Experimental Therapeutics is the programmatic home for basic and clinical investigators involved in a broad spectrum of studies in cancer therapeutics. The goals of the program are: (1) to develop novel agents for the treatment of cancer based upon targets identified in this and other programs, (2) to improve the activities of established classes of drugs by structural modification and/or enhanced understanding of their pharmacological properties, (3) to develop more effective clinical therapeutic regimens within the context of disease-focused working groups. Preclinical drug development continues in the areas of transition-state inhibitors, novel microtubule-stabilizing agents, and a diverse spectrum of immunotherapeutics. Two transition-state inhibitors are now in clinical trials, one advanced. A third is moving forward to the clinic. A monoclonal antibody (moab) to melanin linked to 188-rhenium completed Phase I clinical trials for the treatment of advanced melanoma. Other moab-radionuclides are being developed targeting cervical and pancreatic cancers. An agent for the prevention of the dermatitis due to EGFR inhibitors recently entered a Phase II clinical trial. The spectrum of agents studied has broadened to encompassing aptamers, high-affinity antibodies, agents to block apoptotic pathways or targeted to surface glycans. Research in biologicals is focused on co-inhibitory elements within the immune synapse with the objective of developing agents that modulate tolerance, research activities supported by the expanding capabilities in protein production, synthetic chemistry, x-ray crystallography, NMR, and mass spectroscopy with bioinformatics and systems and computational biology support. Disease-focused working groups encompassing basic and clinical investigators have been expanded in breast, gynecological, lung, and head/neck cancers and in the hematological malignancies. Neuro-oncology and neuroendocrine tumors groups were recently formed. Recruitment of clinical and translational researchers has been enhanced by a recently funded Paul Calabresi Career Development Award for Clinical Oncology Scholars. Access to patients for clinical trials has been enhanced at the affiliated Montefiore Medical Center by the creation of the multidisciplinary Montefiore-Einstein Center for Cancer Care and the recruitment of a cadre of clinician investigators. AECC members play important roles in ECOG-ATRIN, GOG, COG, and the AIDS Malignancy Consortium. There are currently 54 members from 23 departments, supported by 10 NCI grants ($2.6M Direct) and 21 other peer-reviewed cancer-relevant grants ($10.2M Direct). Since the last CCSG review there have been 537 cancer-relevant research papers by members of this program of which 29% represent intraprogrammatic, and 27% represent interprogrammatic publications.

Public Health Relevance

The goal of this program is to develop drugs that are effective in the treatment of cancer. Drugs are designed to inhibit specific target sites within cancer cells. In another approach antibodies linked to radioactive chemicals are targeted to tumor cells. Other studies are exploring the mechanisms by which tumor cells escape immune attack in order to identifying drugs that enhance the immune response to tumors. Groups of physicians focus on specific cancers to develop new therapies with anticancer drugs and radiation.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA013330-40
Application #
8582084
Study Section
Subcommittee G - Education (NCI)
Project Start
1997-06-01
Project End
2018-06-30
Budget Start
2013-08-23
Budget End
2014-06-30
Support Year
40
Fiscal Year
2013
Total Cost
$247,662
Indirect Cost
$51,767
Name
Albert Einstein College of Medicine
Department
Type
DUNS #
110521739
City
Bronx
State
NY
Country
United States
Zip Code
10461
Oudin, Madeleine J; Hughes, Shannon K; Rohani, Nazanin et al. (2016) Characterization of the expression of the pro-metastatic Mena(INV) isoform during breast tumor progression. Clin Exp Metastasis 33:249-61
Lee, Kyeryoung; Tosti, Elena; Edelmann, Winfried (2016) Mouse models of DNA mismatch repair in cancer research. DNA Repair (Amst) 38:140-6
Lee, Chang-Hyun; Rimesso, Gerard; Reynolds, David M et al. (2016) Whole-Genome Sequencing and iPLEX MassARRAY Genotyping Map an EMS-Induced Mutation Affecting Cell Competition in Drosophila melanogaster. G3 (Bethesda) 6:3207-3217
Dam, Tarun K; Talaga, Melanie L; Fan, Ni et al. (2016) Measuring Multivalent Binding Interactions by Isothermal Titration Calorimetry. Methods Enzymol 567:71-95
Díaz-Balzac, Carlos A; Rahman, Maisha; Lázaro-Peña, María I et al. (2016) Muscle- and Skin-Derived Cues Jointly Orchestrate Patterning of Somatosensory Dendrites. Curr Biol 26:2379-87
Poulin, Myles B; Schneck, Jessica L; Matico, Rosalie E et al. (2016) Transition state for the NSD2-catalyzed methylation of histone H3 lysine 36. Proc Natl Acad Sci U S A 113:1197-201
Ito, Kyoko; Turcotte, Raphaël; Cui, Jinhua et al. (2016) Self-renewal of a purified Tie2+ hematopoietic stem cell population relies on mitochondrial clearance. Science 354:1156-1160
Agalliu, Ilir; Gapstur, Susan; Chen, Zigui et al. (2016) Associations of Oral α-, β-, and γ-Human Papillomavirus Types With Risk of Incident Head and Neck Cancer. JAMA Oncol :
Yang, Chia-Ping Huang; Yap, Eng-Hui; Xiao, Hui et al. (2016) 2-(m-Azidobenzoyl)taxol binds differentially to distinct β-tubulin isotypes. Proc Natl Acad Sci U S A 113:11294-11299
Miskolci, Veronika; Wu, Bin; Moshfegh, Yasmin et al. (2016) Optical Tools To Study the Isoform-Specific Roles of Small GTPases in Immune Cells. J Immunol 196:3479-93

Showing the most recent 10 out of 1310 publications